my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In Germany, Abbott has sites in Wiesbaden, Ludwigshafen, Wetzlar and Rangendingen.
Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company currently employs approximately 65,000 people and markets its products in more than 130 countries.
Abbott currently has nearly 4,100 employees working at the Wiesbaden, Ludwigshafen, Wetzlar and Rangendingen sites, and offers a wide range of pharmaceutical and diagnostic products – from prevention and diagnosis to treatment and cure. Thanks to substantial investments in discovery science, we have been able to develop innovative medications which lessen the threat of many diseases. Our pharmaceutical products help patients lead healthier and longer lives.
Industrial Sectors
Contact / Request information
Contact the company and request further information free of charge:
Watchlist
This is where you can add this company to your personal favourites
Abbott's HUMIRA (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn's Disease
Abbott announced that the European Commission has approved HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. With this approval, HUMIRA bec ... more
Abbott to Collaborate with Astellas in CMV Vaccine Trial
Abbott announced that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.U ... more
Abbott's HUMIRA Approved in Europe for Expanded Treatment of Crohn's Disease (CD)
Abbott announced that the European Commission (EC) has approved HUMIRA® (adalimumab) for the treatment of moderately active Crohn's disease (CD) in adult patients who have had an inadequate response to conventional therapy. HUMIRA has been approved for severely active CD in adults in the Eu ... more
Abbott de Mexico, S.A. de C.V.
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comp ... more
To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more
To meet the ever growing needs of modern medicine and combat emerging new diseases, there is a constant demand for improved diagnostic methods, therapeutic approaches and technologies. As a leading manufacturer of health care products, it is Abbott's goal to meet these needs worldwide. In G ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
